Found: 202
Select item for more details and to access through your institution.
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies.
- Published in:
- Rheumatology Advances in Practice, 2024, v. 8, n. 2, p. 1, doi. 10.1093/rap/rkae058
- By:
- Publication type:
- Article
Ultrasound assessment of response to intra-articular therapy in osteoarthritis of the knee.
- Published in:
- Rheumatology, 2015, v. 54, n. 8, p. 1385, doi. 10.1093/rheumatology/keu529
- By:
- Publication type:
- Article
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
- Published in:
- Rheumatology, 2011, v. 50, n. 12, p. 2223, doi. 10.1093/rheumatology/ker253
- By:
- Publication type:
- Article
Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.
- Published in:
- Rheumatology, 2011, v. 50, n. 2, p. 261, doi. 10.1093/rheumatology/keq285
- By:
- Publication type:
- Article
Natural history of the eosinophilia-myalgia syndrome.
- Published in:
- 1991
- By:
- Publication type:
- journal article
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
- Published in:
- Rheumatology, 2024, v. 63, n. 7, p. 1779, doi. 10.1093/rheumatology/kead705
- By:
- Publication type:
- Article
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.
- Published in:
- Rheumatology, 2023, v. 62, n. 4, p. 1417, doi. 10.1093/rheumatology/keac500
- By:
- Publication type:
- Article
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
- Published in:
- Rheumatology, 2023, v. 62, n. 2, p. 606, doi. 10.1093/rheumatology/keac375
- By:
- Publication type:
- Article
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
- Published in:
- Rheumatology, 2023, v. 62, n. 2, p. 617, doi. 10.1093/rheumatology/keac353
- By:
- Publication type:
- Article
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
- Published in:
- Rheumatology, 2021, v. 60, n. 11, p. 5337, doi. 10.1093/rheumatology/keab285
- By:
- Publication type:
- Article
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
- Published in:
- Rheumatology, 2021, v. 60, n. 5, p. 2109, doi. 10.1093/rheumatology/keab119
- By:
- Publication type:
- Article
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis.
- Published in:
- Rheumatology, 2021, v. 60, n. 3, p. 1137, doi. 10.1093/rheumatology/keaa271
- By:
- Publication type:
- Article
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
- Published in:
- Rheumatology, 2020, v. 59, n. 6, p. 1325, doi. 10.1093/rheumatology/kez420
- By:
- Publication type:
- Article
258 Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
257 Secukinumab demonstrates a consistent safety profile with up to 5 years' treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
255 Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two Phase 3 studies, FUTURE 2 and FUTURE 3.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
- Published in:
- Rheumatology, 2018, v. 57, n. 11, p. 1972, doi. 10.1093/rheumatology/key173
- By:
- Publication type:
- Article
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
- Published in:
- Rheumatology, 2017, v. 56, n. 11, p. 1993, doi. 10.1093/rheumatology/kex301
- By:
- Publication type:
- Article
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
- Published in:
- Rheumatology, 2017, v. 56, n. 9, p. 1498, doi. 10.1093/rheumatology/kex174
- By:
- Publication type:
- Article
Efalizumab for the Treatment of Psoriatic Arthritis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2007, v. 11, n. 2, p. 57, doi. 10.2310/7750.2007.00006
- By:
- Publication type:
- Article
Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study.
- Published in:
- Journal of Pain Research, 2014, v. 7, p. 679, doi. 10.2147/JPR.S70200
- By:
- Publication type:
- Article
Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.
- Published in:
- Therapeutic Advances in Musculoskeletal Disease, 2022, p. 1, doi. 10.1177/1759720X221140846
- By:
- Publication type:
- Article
Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
- Published in:
- Arthritis Research & Therapy, 2021, v. 23, n. 1, p. 1, doi. 10.1186/s13075-021-02599-4
- By:
- Publication type:
- Article
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
- Published in:
- Arthritis Research & Therapy, 2021, v. 23, n. 1, p. 1, doi. 10.1186/s13075-021-02554-3
- By:
- Publication type:
- Article
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 3, p. 729, doi. 10.1007/s13555-024-01122-2
- By:
- Publication type:
- Article
FIBROMYALGIA FACTS: FOUNDATIONS FOR ASSESSMENT, CARE, AND TREATMENT STRATEGIES.
- Published in:
- Primary Psychiatry, 2009, v. 16, p. 1
- By:
- Publication type:
- Article
FIBROMYALGIA FACTS: FOUNDATIONS FOR ASSESSMENT, CARE, AND TREATMENT STRATEGIES.
- Published in:
- Primary Psychiatry, 2009, v. 16, p. 1
- By:
- Publication type:
- Article
FIBROMYALGIA: KEY CLINICAL DOMAINS, COMORBIDITIES, ASSESSMENT, AND TREATMENT.
- Published in:
- Primary Psychiatry, 2009, v. 16, p. 6
- By:
- Publication type:
- Article
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 6, p. 2932, doi. 10.1007/s12325-022-02084-7
- By:
- Publication type:
- Article
Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
- Published in:
- ACR Open Rheumatology, 2024, v. 6, n. 5, p. 304, doi. 10.1002/acr2.11657
- By:
- Publication type:
- Article
Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
- Published in:
- ACR Open Rheumatology, 2023, v. 5, n. 8, p. 388, doi. 10.1002/acr2.11556
- By:
- Publication type:
- Article
Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen‐B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
- Published in:
- ACR Open Rheumatology, 2022, v. 4, n. 5, p. 447, doi. 10.1002/acr2.11416
- By:
- Publication type:
- Article
Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
- Published in:
- ACR Open Rheumatology, 2020, v. 2, n. 8, p. 459, doi. 10.1002/acr2.11156
- By:
- Publication type:
- Article
Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
- Published in:
- ACR Open Rheumatology, 2020, v. 2, n. 7, p. 449, doi. 10.1002/acr2.11154
- By:
- Publication type:
- Article
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study.
- Published in:
- ACR Open Rheumatology, 2020, v. 2, n. 1, p. 18, doi. 10.1002/acr2.11097
- By:
- Publication type:
- Article
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.
- Published in:
- Arthritis & Rheumatology, 2024, v. 76, n. 9, p. 1397, doi. 10.1002/art.42921
- By:
- Publication type:
- Article
Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis.
- Published in:
- Arthritis & Rheumatology, 2024, v. 76, n. 6, p. 894, doi. 10.1002/art.42803
- By:
- Publication type:
- Article
Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
- Published in:
- Arthritis & Rheumatology, 2022, v. 74, n. 3, p. 475, doi. 10.1002/art.42010
- By:
- Publication type:
- Article
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 9, p. 1663, doi. 10.1002/art.41716
- By:
- Publication type:
- Article
Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 4, p. 604, doi. 10.1002/art.41553
- By:
- Publication type:
- Article
Reply.
- Published in:
- 2020
- By:
- Publication type:
- Letter to the Editor
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 7, p. 1112, doi. 10.1002/art.40851
- By:
- Publication type:
- Article
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 1, p. 5, doi. 10.1002/art.40726
- By:
- Publication type:
- Article
Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.
- Published in:
- Arthritis & Rheumatology, 2018, v. 70, n. 11, p. 1778, doi. 10.1002/art.40579
- By:
- Publication type:
- Article
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
- Published in:
- Arthritis & Rheumatology, 2016, v. 68, n. 9, p. 2163, doi. 10.1002/art.39700
- By:
- Publication type:
- Article
Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.
- Published in:
- Arthritis & Rheumatology, 2016, v. 68, n. 8, p. 1914, doi. 10.1002/art.39685
- By:
- Publication type:
- Article
Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain.
- Published in:
- Arthritis & Rheumatology, 2016, v. 68, n. 7, p. 1669, doi. 10.1002/art.39612
- By:
- Publication type:
- Article